HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions' translational oncology tools throughout Europe.
Champions' European customers can continue their unique and consultative interactions with the Champions business development and project leadership teams, along with the option of performing the pharmacology work locally. An operations solution in Europe reduces the intercontinental logistics involved with performing the work in the US. This agreement provides Champions greater access to prospective European clients who prefer a local presence.
Ronnie Morris, Chief Executive Offer of Champions Oncology said, "This partnership will enhance the experience of our European customers by providing them with local operational execution. The expansion of our pharmacology services throughout Europe is a multi-year strategic initiative of Champions, and this partnership is a pivotal next step in that plan. This partnership also opens the door to expansion of additional global services, including clinical flow cytometry."
"It was important for us to find a partner that both fit the culture of Champions, and met our high-quality, operational standards", said David DeOrnellis, Vice President and Head of Global Laboratory Operations at Champions Oncology. "We are confident that we found this in TransCure bioServices, and we are excited about the new growth potential throughout Europe."
"A partnership with Champions Oncology is key to growing our international expansion and allow us to apply our hu-mouse expertise in the field of PDX and clinical flow cytometry in Europe for long term customers relationships", said Patrick NEF, Chief Executive Officer and co-founder of TransCure bioServices."
"In our quest to provide the most relevant data and services to our international clients, Patient Derived Xenografts (PDX) models are clearly becoming the gold standard" according to Sebastien Tabruyn, Chief Scientific Officer at TransCure bioServices. "Being able to combine the best of the PDX with our capability to reconstitute the full human immune system in mouse models is a major advance for drug development scientists targeting immuno-oncology like check point inhibitors, CAR-T cells and new anti-cancer combination therapies."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to improve the development and use of oncology drugs. The Company's TumorGraft technology platform is based on the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions to pharmaceutical and biotechnology companies seeking personalized approaches to drug development to lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.
About TransCure bioServices SAS
TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, please refer to www.tcbioservices.com.
Champions Oncology, Inc.
SOURCE: Champions Oncology, Inc.